![conference banner](/images/conference-banner.jpeg)
Abstract
Cyclooxygenase is a key enzyme responsible for metabolisation of arachidonic acid into prostaglandins and thromboxane. This enzyme is the target of non steroidal anti-inflammatory drugs (NSAIDs), used against inflammation and pain. The inducible COX-2 was associated with inflammatory conditions, whereas the constitutive form (COX-1) was responsible for the beneficial effects of the PGs. This observation led to the development of COX-2 inhibitors or “coxibs” of which rofecoxib (Vioxx®) characterized by a methylsulfone moiety and the sulfonamides celecoxib (Celebrex®) and valdecoxib (Bextra®). Initially described as COX-2 “selective” inhibitors, recent reports revealed a nanomolar inhibition activity of the sulfonamide COX-2 inhibitors for several carbonic anhydrase (CA) isoforms, confirmed by X-ray crystal structures for the adducts of celecoxib and valdecoxib with isozyme CA II. This dual activity may help to explain differences in clinical observation between sulfonamide and methylsulfone COX-2 inhibitors. Moreover, the inhibition of CA isozymes, critical for the development and invasion of cancer cells, such as CA II, IX and XII, may constitute an important mechanism of antitumor action of such sulfonamide compounds.
Keywords: COX-2 expression, COX isoforms, thromboxane, CA9 promoter, prostaglandins
Current Topics in Medicinal Chemistry
Title: Dual Carbonic Anhydrase - Cyclooxygenase-2 Inhibitors
Volume: 7 Issue: 9
Author(s): Jean-Michel Dogne, Anne Thiry, Domenico Pratico, Bernard Masereel and Claudiu T. Supuran
Affiliation:
Keywords: COX-2 expression, COX isoforms, thromboxane, CA9 promoter, prostaglandins
Abstract: Cyclooxygenase is a key enzyme responsible for metabolisation of arachidonic acid into prostaglandins and thromboxane. This enzyme is the target of non steroidal anti-inflammatory drugs (NSAIDs), used against inflammation and pain. The inducible COX-2 was associated with inflammatory conditions, whereas the constitutive form (COX-1) was responsible for the beneficial effects of the PGs. This observation led to the development of COX-2 inhibitors or “coxibs” of which rofecoxib (Vioxx®) characterized by a methylsulfone moiety and the sulfonamides celecoxib (Celebrex®) and valdecoxib (Bextra®). Initially described as COX-2 “selective” inhibitors, recent reports revealed a nanomolar inhibition activity of the sulfonamide COX-2 inhibitors for several carbonic anhydrase (CA) isoforms, confirmed by X-ray crystal structures for the adducts of celecoxib and valdecoxib with isozyme CA II. This dual activity may help to explain differences in clinical observation between sulfonamide and methylsulfone COX-2 inhibitors. Moreover, the inhibition of CA isozymes, critical for the development and invasion of cancer cells, such as CA II, IX and XII, may constitute an important mechanism of antitumor action of such sulfonamide compounds.
Export Options
About this article
Cite this article as:
Dogne Jean-Michel, Thiry Anne, Pratico Domenico, Masereel Bernard and Supuran T. Claudiu, Dual Carbonic Anhydrase - Cyclooxygenase-2 Inhibitors, Current Topics in Medicinal Chemistry 2007; 7 (9) . https://dx.doi.org/10.2174/156802607780636717
DOI https://dx.doi.org/10.2174/156802607780636717 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of NMR Metabolomics to Search for Human Disease Biomarkers
Combinatorial Chemistry & High Throughput Screening Current Non-viral Gene Therapy Strategies for the Treatment of Glioblastoma
Current Medicinal Chemistry Nanoprobes for Medical Diagnosis: Current Status of Nanotechnology in Molecular Imaging
Current Nanoscience Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design Nutritional Antioxidants and Adaptive Cell Responses: An Update
Current Molecular Medicine Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications
Current Drug Targets Editorial (Thematic Issue: Mechanisms of Cancer Stem Cell Resistance to Chemotherapy)
Current Signal Transduction Therapy Novel MicroRNA Signature to Differentiate Ulcerative Colitis from Crohn Disease: A Genome-Wide Study Using Next Generation Sequencing
MicroRNA Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Aptamer-based Biosensors: Promising Sensing Technology for Diabetes Diagnosis in Biological Fluids
Current Medicinal Chemistry Current Strategy for Cisplatin Delivery
Current Cancer Drug Targets A Facile and Microwave-assisted Rapid Synthesis of 2-Arylamino-4-(3′-indolyl)- thiazoles as Apoptosis Inducing Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry Exosome: An Emerging Source of Biomarkers for Human Diseases
Current Molecular Medicine Anti-resorptive Drugs and their Impact on Maxillofacial Bone among Cancer Patients
Anti-Cancer Agents in Medicinal Chemistry Platinum(II) and Palladium(II) Complex Compounds as Anti-cancer Drugs. Methods of Cytotoxicity Determination
Current Pharmaceutical Analysis Inhibition of Angiogenesis by Non-Steroidal Anti-Inflammatory Drugs: From the Bench to the Bedside and Back
Current Drug Targets - Inflammation & Allergy Pyruvate Kinase M2: Regulatory Circuits and Potential for Therapeutic Intervention
Current Pharmaceutical Design The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
Current Medicinal Chemistry Hereditary Papillary Renal Carcinoma Type I
Current Molecular Medicine Nitric Oxide as a Marker for Levo-Thyroxine Therapy in Subclinical Hypothyroid Patients
Current Vascular Pharmacology